Early Clinical Development of Synapse-Focused Agent SPG302 for Alzheimer Disease

Peter Vanderklish, PhD, chief science officer at Spingogenix, commented on a recently initiated phase 2 trial assessing investigational SPG302, a synaptic-regenerative agent in development for Alzheimer disease.:

Source: Neurology Read More

Previous PostMigraine Not Directly Linked to Traditional Cardiovascular Disease Risk Factors
Next PostProperly Integrating Newly Approved IPX203 in the Care of Parkinson Disease

Early Clinical Development of Synapse-Focused Agent SPG302 for Alzheimer Disease

Previous PostMigraine Not Directly Linked to Traditional Cardiovascular Disease Risk Factors

Next PostProperly Integrating Newly Approved IPX203 in the Care of Parkinson Disease

Related Posts

<![CDATA[NeuroVoices: Michio Hirano, MD, on Reflecting on Contributions to Neuromuscular Disease Research]]>

<![CDATA[Phase 1/2 VALOR Study to Assess ASP2957 Gene Therapy in Infants With X-Linked Myotubular Myopathy]]>

<![CDATA[How Biotechnology and Advocacy Are Shaping the Future of Neuromuscular Care: John F. Crowley]]>

Categories